GlassScriptPhysician profile
Qianfang Cai
NPI 1396374450
$3,890.43
in general payments reported to CMS, 2019-2025
31 companies · $2,369 in 2025
The $2,369 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $165 · 2024: $1,356 · 2025: $2,369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,890.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,890.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $592.02 | 2023-2025 | Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $520.03 | 2024-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $468.02 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $390.95 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $287.52 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $285.30 | 2024-2025 | |
| Amgen INC. | $235.13 | 2024-2025 | Evenity, Otezla, Repatha |
| Glaxosmithkline, LLC. | $218.25 | 2024-2025 | Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $86.75 | 2024 | Capvaxive |
| Axsome Therapeutics, INC. | $70.84 | 2025 | Symbravo |
| Exact Sciences Corporation | $69.92 | 2025 | Cologuard Collection Kit |
| Biogen, INC. | $64.27 | 2024 | Skyclarys |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.13 | 2024-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $56.32 | 2024-2025 | Eliquis |
| Phathom Pharmaceuticals, INC. | $52.44 | 2024-2025 | Voquezna |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $41.54 | 2023-2024 | Xelstrym |
| Bayer Healthcare Pharmaceuticals INC. | $40.91 | 2025 | |
| Janssen Pharmaceuticals, INC | $37.81 | 2023-2024 | Xarelto |
| Teva Pharmaceuticals USA, INC. | $36.04 | 2023-2024 | Austedo Xr, Ajovy |
| Vertex Pharmaceuticals Incorporated | $35.93 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $34.20 | 2023-2024 | Rexulti |
| Ardelyx, INC. | $31.53 | 2024 | Ibsrela |
| Inspire Medical Systems, INC. | $26.42 | 2025 | Inspire |
| Xeris Pharmaceuticals, INC. | $20.92 | 2024 | Keveyis |
| Corcept Therapeutics | $20.05 | 2025 | Korlym |
| Scpharmaceuticals INC. | $19.97 | 2025 | |
| Abbott Laboratories | $19.66 | 2025 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $17.88 | 2025 | Zoryve |
| Tris Pharma INC | $16.40 | 2025 | Dyanavel Xr |
| Dexcom, INC. | $16.25 | 2025 | Dexcom G6 Transmitter |
| Azurity Pharmaceuticals, INC. | $14.03 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Qianfang Cai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.